Neurology

Delirium is often missed by health providers. Could an AI risk predictor help?
Research shows about one in four adults become delirious during a hospital admission. That’s about 500,000 Canadians a year. Age is a risk factor, as delirium presents in about half of hospitalized patients ages 65 and older.
Study shows a blood test can help identify healthy people at high risk for Alzheimer’s disease
That information could be reassuring or terrifying, but for now it’s a potential tool to speed drug development by helping to identify and enroll high-risk people into studies of possible Alzheimer’s treatments or preventive strategies.

How does wildfire smoke affect your brain today and down the road?

Recent research shows tiny particles from wildfire smoke—known as PM2.5, fine particulate matter—are so small they can travel deep into the lungs. But they don’t always end their journey there.
Canada's Drug Agency recommends funding lecanemab for early-stage Alzheimer's disease

The antibody targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of the disease.
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows

Tau is one part of a toxic duo fueling Alzheimer’s but prior attempts to develop drugs that can target the protein have failed.
What to consider about prescriptions of Lecanemab for early Alzheimer’s

CMAJ authors provide decision-making pathway to help clinicians weigh benefits and risks and engage with patients and caregivers.
NEW DRUG: Kisunla for early Alzheimer’s disease

Get the info you need on this new product, part of our drug news roundup for July.
Can GLP-1 receptor agonists affect the sense of smell or taste?

Large scale study evaluates the association between glucagon-like peptide-1 (GLP-1) receptor agonist use and smell and taste disturbances.
A specific region of the brain has been linked to hard-to-treat hypertension

Study says a cluster of neurons involved in breathing may also drive some cases of treatment-resistant high blood pressure.
Updated recommendations for meningococcal vaccines in children under 2 years

NACI provides guidance on the use of quadrivalent meningococcal vaccines in routine and high-risk immunization programs for children under 2 years of age in Canada.

Delirium is often missed by health providers. Could an AI risk predictor help?

Study shows a blood test can help identify healthy people at high risk for Alzheimer’s disease

How does wildfire smoke affect your brain today and down the road?

Canada's Drug Agency recommends funding lecanemab for early-stage Alzheimer's disease

An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows

What to consider about prescriptions of Lecanemab for early Alzheimer’s

NEW DRUG: Kisunla for early Alzheimer’s disease

Can GLP-1 receptor agonists affect the sense of smell or taste?

A specific region of the brain has been linked to hard-to-treat hypertension

Updated recommendations for meningococcal vaccines in children under 2 years